Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
APLLTD.NS
Strong BuyPremium GrowerAlembic Pharmaceuticals Limited · Healthcare · India · $1.7B · Avg Vol: $1M/d
84
StockRankGet insider-trade alerts
Q
69
V
46
M
66
P/E (TTM)
23.2x
ROE
11.9%
D/E
0.3x
Dividend %
1.5%
COMPANY DESCRIPTION
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.0B | 61.1B | 65.4B | 72.1B | 9.5% | 77.8B | 82.7B | 90.8B | 12.2% |
| EPS (INR) | 17.40 | 31.33 | 29.68 | 34.33 | 25.4% | 35.25 | 33.75 | 43.82 | 13.0% |
| Shares | 196.6M | 196.6M | 196.6M | 196.6M | 0.0% | 196.6M | — | — | — |
| Debt | 7.2B | 5.1B | 12.6B | 14.3B | 25.6% | 14.3B | — | — | — |
| Equity | 43.7B | 48.2B | 51.9B | 56.7B | 9.1% | — | — | — | — |
| Op CF | 7.2B | 8.0B | 879.7M | 7.8B | 2.6% | 7.8B | — | — | — |
| Inv CF | -4.5B | -3.2B | -5.7B | -5.1B | — | — | — | — | — |
| Fin CF | -2.6B | -4.4B | 4.4B | -1.6B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+0.7%
SMA 50SMA 200
Close
$8.59
RSI (14)
50.0
52W High
$10.34
From 52W High
0.8%
SCORE BREAKDOWN
Quality
69
ROIC
12.8%78.1
ROE
11.9%75.7
GP/Assets
62.7%91.8
Op. Margin
10.9%64.9
FCF/Assets
3.3%61.7
Piotroski
668.8
Int. Cover
8.4x59.3
D/E Ratio
0.25x45.3
Current Ratio
1.75x33.3
Value
46
P/E (TTM)
23.2x52.9
EV/EBITDA
15.1x47.9
P/FCF
55.4x26.6
P/B
2.8x48.3
P/S
2.1x67.9
Div Yield
1.5%40.9
Momentum
66
52W High %
83%72.2
RS 6M
21%80.9
SMA 50/200
1.05x67.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+36%45.8
Q Growth
12%48.4
FUNDAMENTALS
Market Cap
$1.7B
P/E (Forward)
17.0x
Gross Margin
70.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APLLTD.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| APLLTD.NS | Alembic Pharmaceuticals Limited(you) | $1.7B | 84 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| NATCOPHARM.NS | NATCO Pharma Limited | $1.6B | 72 | Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
| AKUMS.NS | Akums Drugs and Pharmaceuticals Limited | $1.2B | 95 | Strong Buy |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%